Compounds > succinobucol
Page last updated: 2024-09-05

succinobucol and Coronary Restenosis

succinobucol has been researched along with Coronary Restenosis in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L1
Doggrell, SA1
Grégoire, J; L'Allier, PL; Lavoie, MA; Tardif, JC1
Tardif, JC2
Franks, AM; Gardner, SF1
Eisert, C; Malinin, A; Ong, S; Serebruany, VL1
Douglas, JS1

Reviews

7 review(s) available for succinobucol and Coronary Restenosis

ArticleYear
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
    Expert opinion on investigational drugs, 2003, Volume: 12, Issue:11

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Disease Models, Animal; Endothelium, Vascular; Humans; Probucol

2003
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
    Current opinion in lipidology, 2003, Volume: 14, Issue:6

    Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; ortho-Aminobenzoates; Oxidative Stress; Probucol; Sirolimus; Vitamins

2003
Antioxidants and atherosclerosis: emerging drug therapies.
    Current atherosclerosis reports, 2005, Volume: 7, Issue:1

    Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Humans; Oxidative Stress; Probucol

2005
AGI-1067: a novel vascular protectant for prevention of restenosis.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:1

    Topics: Animals; Antioxidants; Clinical Trials as Topic; Coronary Restenosis; Drugs, Investigational; Humans; Molecular Structure; Probucol

2006
Antioxidants: the good, the bad and the ugly.
    The Canadian journal of cardiology, 2006, Volume: 22 Suppl B

    Topics: Angioplasty, Balloon, Coronary; Antioxidants; Atherosclerosis; Coronary Restenosis; Humans; Oxidative Stress; Probucol; Vitamins

2006
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:4

    Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosis; Cytokines; Disease Progression; Humans; Hypolipidemic Agents; Oxidative Stress; Platelet Aggregation Inhibitors; Probucol; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2007
Pharmacologic approaches to restenosis prevention.
    The American journal of cardiology, 2007, Sep-03, Volume: 100, Issue:5A

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome

2007

Trials

1 trial(s) available for succinobucol and Coronary Restenosis

ArticleYear
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
    Circulation, 2003, Feb-04, Volume: 107, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary Disease; Coronary Restenosis; Coronary Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Probucol; Stents; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency

2003